Name | OXFBD04 |
---|
Description | OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity[1]. |
---|---|
Related Catalog | |
Target |
BRD4:166 nM (IC50) |
In Vitro | OXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth[1]. OXFBD04 (10 µM; for 10, 24, or 48 hours) induces MYC suppression in MCF7 breast cancer cells[1]. Cell Viability Assay[1] Cell Line: A498 (renal), HT-29 (colon), and MCF7 (breast) cancer cell lines Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time: 48 hours Result: Inhibited cancer cell lines growth. |
In Vivo | OXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t1/2=388 min). OXFBD04 has CLint of 3.57 µL/min/mg[1]. |
References |
Molecular Formula | C17H16N2O3 |
---|---|
Molecular Weight | 296.32 |